366 related articles for article (PubMed ID: 37354562)
1. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
[TBL] [Abstract][Full Text] [Related]
2. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC
Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084
[TBL] [Abstract][Full Text] [Related]
4. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
[TBL] [Abstract][Full Text] [Related]
5. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
6. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
8. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
[TBL] [Abstract][Full Text] [Related]
9. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
[TBL] [Abstract][Full Text] [Related]
10. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
11. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
Bajaj HS; Aberle J; Davies M; Donatsky AM; Frederiksen M; Yavuz DG; Gowda A; Lingvay I; Bode B
Ann Intern Med; 2023 Nov; 176(11):1476-1485. PubMed ID: 37748181
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
Shetty S; Suvarna R
Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
[TBL] [Abstract][Full Text] [Related]
13. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J; Frías JP; Rodbard HW; Tofé S; Sears E; Huh R; Fernández Landó L; Patel H
JAMA; 2023 Nov; 330(17):1631-1640. PubMed ID: 37786396
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
15. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
[TBL] [Abstract][Full Text] [Related]
16. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis.
Mukhopadhyay P; Chatterjee P; Pandit K; Sanyal D; Ghosh S
Endocr Pract; 2024 Feb; 30(2):128-134. PubMed ID: 37984730
[TBL] [Abstract][Full Text] [Related]
20. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
